Maze Therapeutics, Inc. Common Stock (MAZE) Q3 2024 Earnings
MAZE·Reported September 30, 2024·Before market open
Maze Therapeutics, Inc. Common Stock reported Q3 2024 revenue of $2.5M. Diluted EPS came in at $-0.57.
Revenue
$2.5M
Diluted EPS
$-0.57
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q3 2024 Earnings FAQ
Common questions about Maze Therapeutics, Inc. Common Stock's Q3 2024 earnings report.
Maze Therapeutics, Inc. Common Stock (MAZE) reported Q3 2024 earnings on September 30, 2024 before market open.
Maze Therapeutics, Inc. Common Stock reported revenue of $2.5M and diluted EPS of $-0.57 for Q3 2024.